Page	1	of	3
1 ago		$\mathbf{o}_{\mathbf{I}}$	J

	01150
Marked-Up Version	MAY 2 6 2004 8

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Transfer of Commerce

Atty. Docket No. AP32738 066876.0103

Serial No. 09/955,877

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Said I.A. SHALABY et al.

Filing Date September 19, 2001 Group 1654

**U.S. PATENT DOCUMENTS** 

Exam. Init.			Docum	nent N	o.			Date	Name	Class	Subclass	Filing Date ifAppropriate
	5	8	7	6	7	2	8	03/02/1999	Kass HD et al.			
•	5	8	7	4	8	0	4	02/23/1999	Rogers SP			
	5	6	4	8	0	8	9	07/15/1997	Shawkat T			
		<u> </u>		<b>L</b>	J.	1	1. <u></u>	FOREIGN PA	TENT DOCUMENT			
												Translator

	Document No.							Date	Country	Class	SubClass	Trans Yes	slator No
		7	9	3	9	6	4	09/10/1999	Europe (EP)				

•	OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)
	Harvard School of Public Health Jan 2004, <a href="http://www.researchmatters.harvard.edu/story.php?article_id=673">http://www.researchmatters.harvard.edu/story.php?article_id=673</a>
	Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
	Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS, Wall Street Journal December 8, 2003 <a href="http://online.wsj.com/article/0">http://online.wsj.com/article/0</a> ,SB107083909136415400-email,00.html>
	 Abramowicz M, ed., "Enfuvirtide (Fuzeon) for HIV Infection" Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
	El-Awady, et al., Chem. Clinical Clinica Chimica Acta, 283(1-2):1-14 (1999);
	McHutchison et al., "Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment fro Chronic Hepatitis C", New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner Date Considered

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Page	2	of	3

	0	PETCH	
Marked-Up Version	MAY	2 6 2004	
	0	Ĕ/	

Form PTO-14	49 U.S. Department of Co	merce
(REV. 2-82)	Patent and mademarts	fice

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877	
Applicant		

Said I.A. SHALABY et al.

Filing Date Group September 19, 2001 1654

Yokozbawa Yokozawa, et al., J. Traditional Medicine, 15(4):202-20715(1):45-51 (1998)
Alter, M.J., Hepatology, 26(1):625-65562S-65S (1997)
 Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);
D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);
Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);
D.C. Dale and D.D. Federman, eds., Sci. Amer. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);
HippsHibbs, et al., J. Infect. Dis. 168:789-790 (1993);
Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);
Fields Flint SJ et al., Principles of Virology: Molecular Biology, Pathogenesis, and Control 2nd ed, New York, Raven Press, ASM Press, Washington DC, 1990-p691, p.691;
Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);
Medicinal Plants of North Africa, pp. 74-75, 92-93 (1983);
Bergmeyer and Horder, Clin. Chen. Clinica Chemica Acta 105147 f.105:147f-154f (1980);
Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, John Wiley & Sons, New York,
p.169 (1980);

NY02:472768.1

Date Considered Examiner

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

•	OIPECO		
Marked-Up <sup>v</sup>			Page 3 of 3
Form PTO-14 (REV. 2-82)	149 U.S. Department of Companies Patent and Trademark (1986)	Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877
INFORM	ATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Said I.A. SHALABY et al.	
(1	Use several sheets if necessary)	Filing Date September 19, 2001	Group 1654
			120 125
	Bergmeyer H. U. Principles Methods of Enzym	natic Analysis. Verlag Chemic, (1978)	), pp. 130-133;
	Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (19	970);	
-	Linus Pauling, General Chemistry, New York,	Raven Press Dover Publications, Inc.	, 1970, p 744.
	<u> </u>		
		<u> </u>	
1			
NY02:472768.	1	·	
Examiner	Date	Considered	

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.